Capital International Inc. CA Buys 16,108 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Capital International Inc. CA lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 191,341 shares of the pharmaceutical company’s stock after purchasing an additional 16,108 shares during the period. Capital International Inc. CA owned about 0.08% of Vertex Pharmaceuticals worth $74,937,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Chesapeake Asset Management LLC raised its holdings in Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 33 shares during the last quarter. Colonial Trust Co SC raised its holdings in shares of Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 38 shares during the period. Total Investment Management Inc. bought a new position in Vertex Pharmaceuticals in the second quarter worth approximately $33,000. Financial Network Wealth Advisors LLC increased its stake in Vertex Pharmaceuticals by 50.9% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock valued at $34,000 after purchasing an additional 29 shares in the last quarter. Finally, Y.D. More Investments Ltd increased its position in shares of Vertex Pharmaceuticals by 345.0% during the third quarter. Y.D. More Investments Ltd now owns 89 shares of the pharmaceutical company’s stock worth $35,000 after acquiring an additional 69 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on VRTX shares. Stifel Nicolaus upped their price target on Vertex Pharmaceuticals from $445.00 to $466.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Evercore increased their target price on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Leerink Partners raised their price target on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research report on Monday, December 29th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $577.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Finally, Oppenheimer upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 target price on the stock in a research note on Friday, February 13th. Twenty-two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $542.00.

Vertex Pharmaceuticals Stock Up 0.9%

Vertex Pharmaceuticals stock opened at $460.87 on Tuesday. The firm has a 50 day moving average price of $467.50 and a 200-day moving average price of $435.79. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68. The company has a market capitalization of $117.07 billion, a P/E ratio of 30.06 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. During the same period last year, the firm posted $3.98 EPS. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: RAINIER Phase 3 interim analysis met the primary endpoint and all secondary endpoints at Week 36, with treated patients showing the intended benefit versus placebo — a major validation step for povetacicept in IgA nephropathy. Vertex Announces Positive Week 36 Interim Analysis Results (BusinessWire)
• Positive Sentiment: Management plans an FDA filing for povetacicept by March, accelerating the regulatory timeline and shortening the path to potential commercialization if final data and review go smoothly. Vertex Stock Surges After Positive Kidney Disease Trial Results (Blockonomi)
• Positive Sentiment: Analysts have reiterated and strengthened bullish views — William Blair’s Myles Minter reiterated a Buy and highlighted increased confidence in povetacicept’s commercial potential, supporting upside to consensus models. Analyst Confidence Boosts Buy Thesis (TipRanks)
• Positive Sentiment: Market reaction: shares rallied in extended trading after the release; coverage notes the asset was acquired in a prior multibillion-dollar deal and is viewed as having “best‑in‑class” potential in a competitive kidney disease market. Vertex Kidney Drug Hits Mark in Late-Stage Study (BioPharmaDive)
• Neutral Sentiment: The result cited is an interim analysis of an ongoing trial — final RAINIER readout, full safety dataset, and regulatory review still lie ahead, so approval and peak sales remain subject to execution and FDA assessment. Press Release / Interim Analysis Details (Yahoo Finance)

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Charles F. Wagner, Jr. sold 9,532 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $461.00, for a total transaction of $4,394,252.00. Following the sale, the executive vice president owned 37,725 shares of the company’s stock, valued at $17,391,225. The trade was a 20.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Mark E. Bunnage sold 2,021 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $930,529.03. Following the sale, the executive vice president directly owned 12,914 shares in the company, valued at $5,945,993.02. This trade represents a 13.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 91,156 shares of company stock worth $42,845,497 in the last three months. Corporate insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.